Elias I.
- Country
- Greece
- Department
- 3rd University Pediatric Department
Research Overview
- C3601008 - A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION
- Phase 3 Randomized Study of Echinocandin Followed by Ibrexafungerp vs. Echinocandin Followed by Fluconazole in Invasive Candidiasis/Candidemia
- Evaluation of Pharmacokinetics, Safety, and Tolerability of Intravenous and Oral Posaconazole in Pediatric Patients with Invasive Fungal Infections
Data & Insights
Has run more than one trial at 64 of 216 partner sites.
Specializations
Infectious Disease Management
The investigator specializes in treating serious gram-negative bacterial infections with particular emphasis on complex pediatric cases from 9 months to under 18 years of age.
- Blood Stream Infections
- Complicated Intra-abdominal Infections
- Sepsis Management
Focuses on developing therapeutic approaches for life-threatening bacterial infections in young patients.
Respiratory Care
Demonstrates expertise in treating severe respiratory conditions, particularly focusing on hospital-acquired infections and complications.
- Hospital-Acquired Pneumonia
- Ventilator-Associated Pneumonia
Specializes in respiratory infection management in critical care settings.
Urological Infections
Concentrates on treating complicated urinary tract infections in pediatric populations.
- Complex UTI Management
- Antimicrobial Therapy
Explores innovative therapeutic approaches for resistant urinary tract infections in young patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.